Do adherence rates and glaucomatous visual field progression correlate?

Gemma C M Rossi, Gian Maria Pasinetti, Luigia Scudeller, Rosella Radaelli, Paolo Emilio Bianchi

Research output: Contribution to journalArticle

Abstract

Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9%±27.8% after 1 month of follow-up and 76.8%±20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p

Original languageEnglish
Pages (from-to)410-414
Number of pages5
JournalEuropean Journal of Ophthalmology
Volume21
Issue number4
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Visual Fields
Timolol
Visual Field Tests
Chi-Square Distribution
Glaucoma
Retrospective Studies
Travoprost

Keywords

  • Adherence
  • Glaucoma
  • Monitoring tools
  • Monotherapy
  • Travatan dosing aid®
  • Visual field progression

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Do adherence rates and glaucomatous visual field progression correlate? / Rossi, Gemma C M; Pasinetti, Gian Maria; Scudeller, Luigia; Radaelli, Rosella; Bianchi, Paolo Emilio.

In: European Journal of Ophthalmology, Vol. 21, No. 4, 07.2011, p. 410-414.

Research output: Contribution to journalArticle

@article{f950321098b8494db8494a40cc5cc79b,
title = "Do adherence rates and glaucomatous visual field progression correlate?",
abstract = "Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid{\circledR} (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9{\%}±27.8{\%} after 1 month of follow-up and 76.8{\%}±20.9{\%} at 12 months. A total of 25 (71.4{\%}) patients with stable VF had a median adherence rate (IQR) of 85{\%} (75{\%}-97{\%}); patients who worsened (n=10; 28.6{\%}) recorded a median (IQR) adherence of 21{\%} (9{\%}-45{\%}) (p",
keywords = "Adherence, Glaucoma, Monitoring tools, Monotherapy, Travatan dosing aid{\circledR}, Visual field progression",
author = "Rossi, {Gemma C M} and Pasinetti, {Gian Maria} and Luigia Scudeller and Rosella Radaelli and Bianchi, {Paolo Emilio}",
year = "2011",
month = "7",
doi = "10.5301/EJO.2010.6112",
language = "English",
volume = "21",
pages = "410--414",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "4",

}

TY - JOUR

T1 - Do adherence rates and glaucomatous visual field progression correlate?

AU - Rossi, Gemma C M

AU - Pasinetti, Gian Maria

AU - Scudeller, Luigia

AU - Radaelli, Rosella

AU - Bianchi, Paolo Emilio

PY - 2011/7

Y1 - 2011/7

N2 - Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9%±27.8% after 1 month of follow-up and 76.8%±20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p

AB - Purpose. To assess the relation between visual field progression and adherence rate in patients with glaucoma using Travatan Dosing Aid® (TDA). Methods. In this 36-month retrospective study, 35 patients with primary open-angle glaucoma on travoprost or travoprost/timolol fixed combination monotherapy were submitted to ophthalmic examination and to visual field (VF) test from 2007 to 2009. Adherence was recorded with TDA. The association between VF progression (from 2007 to the end of the follow-up period) and a number of predictors (adherence rates at 12 months) was tested by means of chi-square test (or Fisher exact test) or Mann-Whitney test as appropriate. Results. The mean (±SD) adherence rates were 71.9%±27.8% after 1 month of follow-up and 76.8%±20.9% at 12 months. A total of 25 (71.4%) patients with stable VF had a median adherence rate (IQR) of 85% (75%-97%); patients who worsened (n=10; 28.6%) recorded a median (IQR) adherence of 21% (9%-45%) (p

KW - Adherence

KW - Glaucoma

KW - Monitoring tools

KW - Monotherapy

KW - Travatan dosing aid®

KW - Visual field progression

UR - http://www.scopus.com/inward/record.url?scp=79957871972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957871972&partnerID=8YFLogxK

U2 - 10.5301/EJO.2010.6112

DO - 10.5301/EJO.2010.6112

M3 - Article

C2 - 21140373

AN - SCOPUS:79957871972

VL - 21

SP - 410

EP - 414

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 4

ER -